[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
July 2017

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors

Author Affiliations
  • 1Departments of Oncology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
  • 2Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
  • 3Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
JAMA Dermatol. 2017;153(7):723-725. doi:10.1001/jamadermatol.2017.0500

Fibroblast growth factors (a family of 22 distinct polypeptides) and their transmembrane tyrosine kinase receptors (FGFR1-FGFR4) play a critical role in several cancers.1 Overexpression, gain-of-function mutations and gene fusions are the main aberrant alterations leading to oncogenic function of FGFR.2 Lucitanib and dovitinib were the first nonselective FGFR tyrosine kinase inhibitors (TKIs) investigated in advanced cancers.

×